Showing recent highlights
What's New
PubMed · June 1, 2026
Researchers found that a rare lung complication of lupus called shrinking lung syndrome — where the lungs gradually lose volume and feel harder to fully inflate — most often showed up in younger women, with shortness of breath being the most common symptom in every single case they reviewed. The condition appears to involve the diaphragm (the muscle just below the lungs that helps with breathing) not moving as fully as it should, making it harder to take deep breaths. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that women with lupus who watched a contraceptive education video through a mobile app felt more interested in using birth control right after watching it — but four weeks later, they were actually less likely to be using effective birth control compared to women who received in-person counseling, mostly because they didn't follow through with clinic visits to get their chosen method. This suggests that while app-based education can spark interest, having someone available in person may help people act on that interest. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a weekly under-the-skin injection of a drug called anifrolumab helped more adults with moderate to severe lupus get their disease under control compared to a placebo (an inactive treatment) — and some patients were even able to lower their steroid doses at the same time, which matters because long-term steroid use can cause its own health problems. Lupus is an autoimmune condition where the body's immune system mistakenly attacks its own tissues, causing inflammation and flares throughout the body. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether anifrolumab (Saphnelo) might help reduce the patient's lupus symptoms if the patient's current medicines aren't working well enough.
What's New
PubMed · June 1, 2026
Researchers found that belimumab — a medication used to treat lupus — can be given as an under-the-skin injection to children and teenagers with lupus, with dosing adjusted based on the child's weight. The drug reached similar levels in the body as seen in adults, and the approach appeared to work reasonably well across different weight groups. This is early research and hasn't yet changed treatment guidelines.
Medications
The Lancet · May 29, 2026
Researchers found that a medication called dapirolizumab pegol is being explored as a new treatment option for people with lupus, an autoimmune disease where the body's immune system mistakenly attacks its own tissues. The study looked at how this drug works by targeting a specific part of the immune system to help reduce the disease's activity, which can cause a wide range of symptoms throughout the body. This appears to be a new potential option rather than a safety update or standard recommendation.
Ask your doctor: Ask the doctor whether dapirolizumab pegol might be a treatment option for the patient's lupus, since it works in a new way by targeting CD40.
What's New
The Lancet · May 29, 2026
Researchers found that a new medication called dapirolizumab pegol helped reduce disease activity in people with lupus — meaning patients had fewer or less severe symptoms compared to those who received a dummy treatment. Lupus is a condition where the immune system mistakenly attacks the body's own tissues, so finding new ways to calm that activity is a big deal for people living with it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 23, 2026
A study found that tiny calcium deposits in the spleen — spotted on imaging scans — may sometimes be an early sign of lupus, an autoimmune disease where the immune system mistakenly attacks the body's own tissues. Researchers reviewed 30 cases and noticed a recognizable pattern on scans, and found that these deposits could worsen during lupus flare-ups, occasionally causing the spleen to gradually stop working properly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 22, 2026
Researchers found that among pregnant women with lupus (an immune system condition where the body mistakenly attacks its own tissues), those who took hydroxychloroquine — a common lupus medication — were significantly less likely to develop gestational diabetes (a type of high blood sugar that develops during pregnancy) or have a baby with poor growth in the womb, compared to those who didn't take it. The medication didn't show a clear effect on other pregnancy complications like early delivery or high blood pressure during pregnancy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 19, 2026
Researchers found that a drug called anifrolumab, which works by blocking a protein in the immune system called type I interferon — a protein that is overactive in lupus — showed promising results for people with a rare and difficult-to-treat form of lupus called lupus panniculitis, which causes painful inflammation and damage in the deeper layers of the skin. Across 16 patients, most saw their skin symptoms improve significantly, and many were able to reduce or stop taking steroids, which is meaningful because long-term steroid use carries its own health risks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 15, 2026
Researchers found that people with lupus — an autoimmune disease where the body's immune system attacks its own tissues — appear to be more than twice as likely to develop coronary artery disease (a condition where the arteries that supply blood to the heart become narrowed or blocked) compared to people without lupus. This finding came from combining data across 13 studies involving millions of participants, and was also supported by a type of genetic analysis designed to test whether the link is truly causal, meaning lupus itself may be contributing to the increased heart risk rather than just happening alongside it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 9, 2026
Researchers found that a new oral medication called enpatoran — which works by blocking certain signals in the immune system that are thought to drive lupus — was studied in people with moderate-to-severe lupus across 22 countries. The trial looked at different doses of the drug to see which might work best at reducing lupus disease activity over 24 weeks, compared to a dummy pill. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · May 5, 2026
Researchers found that belimumab (brand name Benlysta) — a biologic medication, meaning it's made from living cells and works by targeting a specific part of the immune system — helped children with lupus control their disease better than standard treatment alone. The study found that children taking it had significantly less disease activity, fewer lupus flares (sudden worsening of symptoms), and better kidney outcomes, with 94% of those with kidney-related lupus achieving full remission after 12 months. This is considered a relatively new option, as Benlysta is the first biologic approved specifically for children over age 5 with lupus, and this analysis of real-world data adds to the growing evidence about how well it works over time.
What's New
PubMed · May 5, 2026
Researchers found that a new way of measuring how well lupus is being controlled — called the SLE-DAS Responder Index — did a strong job of predicting which patients were actually feeling better in their daily lives. People whose scores improved by a meaningful amount were also less likely to have a sudden worsening of their lupus (called a flare) and needed less steroid medication over time. This matters because better measuring tools can help doctors more accurately judge whether a treatment is truly working for someone with lupus. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers found that taking vitamin D supplements may help reduce disease activity in people with lupus — meaning it could help calm the immune system's overreaction that causes lupus symptoms. The analysis, which combined results from 10 studies involving 847 people, also found improvements in certain immune markers in the blood (called complement proteins C3 and C4), which doctors use to track how active lupus is. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers found that about 1 in 22 people with lupus — an autoimmune disease where the immune system mistakenly attacks the body — may experience psychosis, a serious condition where a person loses touch with reality and may hear or see things that aren't there, or have false fixed beliefs. This happened most often within the first two years after a lupus diagnosis and was more likely in people whose lupus was more active or who had certain proteins in their blood linked to immune system activity. Understanding who is at higher risk could help doctors watch for these symptoms earlier and respond more quickly. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · May 1, 2026
A study found that African American people with lupus who got to choose their own mix of self-management tools — such as a support group, an online message board, a mailed arthritis kit, or a self-management program — showed improvements in handling stress and managing pain more often using positive coping techniques, like relaxation or reframing how they thought about pain. Researchers found this 'pick your own tools' approach worked better than giving everyone the same single program. The study focused on African American patients because lupus tends to be more severe and harder to manage in this group.
What's New
PubMed · May 1, 2026
Researchers found that people with lupus who carry a certain gene variation — called CYP2C19*2, which affects how the body breaks down certain medications — may be less likely to experience harmful side effects from a strong immune-suppressing drug called cyclophosphamide, which is commonly used to treat lupus and lupus-related kidney problems. This matters because cyclophosphamide can cause serious side effects, and knowing someone's genetic makeup ahead of time could one day help doctors predict who is more at risk. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 27, 2026
Researchers found that people with lupus who develop a serious infection inside the sac surrounding the heart — called septic pericarditis — face a very high risk of a life-threatening emergency, where fluid builds up and squeezes the heart (known as cardiac tamponade), almost always requiring urgent drainage. The study also highlighted that this dangerous infection can be easy to miss in lupus patients because its symptoms, like shortness of breath, can look a lot like a lupus flare rather than an infection. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 18, 2026
Researchers found that infusions of special stem cells taken from umbilical cords — cells that can help calm an overactive immune system — showed promising results for people with lupus that had stopped responding to standard treatments, specifically a serious form that attacks the kidneys. More than half of the patients in the study saw their kidneys respond positively within a year, and people whose kidneys were still functioning reasonably well at the start of treatment tended to do even better. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 17, 2026
Researchers found that mizoribine — a medication used to calm the immune system — may help people with lupus nephritis, which is when lupus attacks the kidneys, by improving kidney response rates and reducing protein in the urine (a sign that the kidneys are leaking when they shouldn't be). The analysis also looked at how safe the drug was across multiple studies, suggesting it could be a useful option alongside other treatments. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 8, 2026
A study found that anifrolumab, a biologic medication used to treat lupus, helped patients reach lower disease activity and even remission — meaning their lupus symptoms were much better controlled — whether or not they had previously tried immune-suppressing medications. This is encouraging because it suggests the medication may be effective even earlier in treatment, before other drugs have been attempted, and it appeared to be well tolerated in both groups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
Researchers found that certain medications — including methotrexate, anifrolumab, and baricitinib — may help control joint pain and swelling in people with lupus, a condition where the immune system mistakenly attacks the body. These treatments were compared to a placebo (an inactive treatment) across five studies involving nearly 1,500 patients, and the results suggest they could be useful options beyond the current standard approach of antimalarial drugs and low-dose steroids. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
Researchers found that a drug called obinutuzumab may help people with lupus nephritis — a serious form of lupus that attacks the kidneys — achieve better kidney recovery compared to a placebo (a dummy treatment with no active medicine). In two studies involving nearly 400 patients, roughly 41–46% of those who received obinutuzumab showed meaningful kidney improvement, and significantly more patients saw reductions in protein leaking into their urine, which is a key sign that the kidneys are under stress. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
Researchers found that African American women with lupus — a condition where the immune system mistakenly attacks the body — who took part in a peer-mentoring program reported lower symptom severity over time, including fewer and less intense flares (episodes when symptoms suddenly get worse). Perhaps the most surprising finding was that the women who served as mentors themselves also saw meaningful improvements in their symptoms, suggesting that helping others may offer real health benefits in return. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
Researchers found that a simple blood measurement called the neutrophil-to-lymphocyte ratio (NLR) — which compares two types of white blood cells to get a sense of inflammation — is higher in people with lupus than in healthy people, and tends to rise when the disease is more active or affecting the kidneys. However, the connection between this number and how active lupus actually is turned out to be quite weak, and factors like a person's ethnic background and the medications they take can change the results significantly, making it unreliable on its own. The researchers concluded that while NLR might play a small supporting role alongside other tests, it shouldn't be used by itself to track lupus activity. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · April 1, 2026
Researchers found that a kidney complication of lupus called lupus podocytopathy — where certain kidney cells become damaged — is often overlooked and not well understood, partly because current medical guidelines don't specifically address it. By reviewing 26 studies covering nearly 260 patients, researchers found that most people affected were young women, and the condition often appeared early in their lupus diagnosis, showing up as high levels of protein leaking into the urine (a sign the kidneys aren't filtering properly). The good news is that most patients did well with treatment using steroids, suggesting this condition may respond more favorably than other kidney complications of lupus — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 11, 2026
Researchers found that people with lupus who had certain signs of high disease activity in their blood — like elevated antibodies and low complement proteins (which help the immune system) — were much more likely to respond well to biologic treatments, a category of medicines made from living cells that target specific parts of the immune system. In fact, for every 6 or 7 people with these blood markers who received a biologic, one extra person improved compared to standard treatment. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 1, 2026
Researchers found that a traditional herbal extract called Tripterygium glycosides — taken from a plant called Tripterygium wilfordii — may help people with lupus (a condition where the immune system mistakenly attacks the body) by improving kidney function, calming overactive immune responses, and reducing disease activity when combined with standard treatment. The study also found it may lower some side effects like nausea and rash, though it appeared to raise the chance of irregular menstrual cycles. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 1, 2026
Researchers found that some people with lupus — especially those diagnosed at a younger age — can develop a rare brain condition where the white matter (the tissue that helps different parts of the brain communicate) becomes damaged in a way that looks similar to a genetic brain disease called leukodystrophy. In a review of 33 cases, the most common warning signs were headaches, seizures, and changes in consciousness, and brain scans showed widespread bright spots in the white matter. Most patients responded reasonably well to strong anti-inflammatory treatments. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · March 1, 2026
Researchers found that lupus can affect the kidneys — a condition called lupus nephritis — and right now, doctors usually need to do a kidney biopsy (a procedure where a tiny piece of kidney tissue is removed and examined) to understand how much damage is happening. This study reviewed over 100 potential 'biomarkers' — measurable substances in the blood or urine that could someday act as a less invasive window into kidney health — and identified five that show early promise for tracking kidney inflammation and scarring without a biopsy. This matters because a reliable blood or urine test could make it easier and safer to monitor kidney health over time in people with lupus. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.